Triple threat: new combo aims to tame metastatic prostate cancer
NCT ID NCT03246347
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding enzalutamide to standard hormone therapy and chemotherapy can better control metastatic prostate cancer that still responds to hormones. About 40 men with advanced disease will receive all three drugs. The main goal is to see how many achieve a very low PSA level at one year, with secondary goals including tumor shrinkage and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Androgen deprivation therapy (ADT), docetaxel, and enzalutamide
- What this could lead to
- If successful, this combination could offer a more effective way to control metastatic prostate cancer for longer, potentially delaying disease progression.
- What could go wrong
- This is a small, early-phase trial (40 participants) with no placebo group. The added drug may increase side effects without clear benefit, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks